1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. NovAccess Global Inc (PK) (XSNX)
  7. Quote


NovAccess Global (PK) Stock Price

-0.0698 (-13.43%)
Volume 3,708
Bid Price 0.253
Ask Price 0.75
News -
Day High 0.45


52 Week Range


Day Low 0.45
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
NovAccess Global Inc (PK) XSNX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0698 -13.43% 0.45 16:28:06
Open Price Low Price High Price Close Price Prev Close
0.45 0.45 0.45 0.45 0.5198
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3 3,708 $ 0.45 $ 1,669 - 0.296 - 0.97
Last Trade Time Type Quantity Stock Price Currency
13:59:04 8 $ 0.4105 USD


Draw Mode:

NovAccess Global Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.08M 13.51M 1.58M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
8.43k $ - - - -

more financials information »

NovAccess Global (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XSNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.49050.520.440.51787749,293-0.0405-8.26%
1 Month0.730.750.440.530158311,212-0.28-38.36%
3 Months0.550550.750.32770.569959612,406-0.10055-18.26%
6 Months0.420.970.32770.602351210,3980.037.14%
1 Year0.450.970.2960.56661278,6090.000.0%
3 Years0.00070.970.00020.00131412,504,8090.449364,185.71%
5 Years0.0010.970.00010.00134463,830,6820.44944,900.0%

NovAccess Global (PK) Description

NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient's own immune system to attack the cancer. We have expertise in successfully executing clinical trials, bringing products to market and increasing market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells. NovAccess operates as a research and development (R&D) company out of Ohio and California, and our executive management and scientific advisory board provides over 15 years of extensive experience in all aspects of biopharmaceutical R&D and commercialization of drug candidates. We guide our performance by striving to deliver consistently on the following core objectives: (1) Accountability- taking responsibility for providing safe and effective options for patients; (2) Integrity- doing what is ethically right for the patient; (3) Excellence- doing your best and working hard; and (4) Teamwork- bringing together a strong working team to deliver the best products for brain tumor patients.

Your Recent History
NovAccess ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.